

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI XDC CAYMAN INC.

藥明合聯生物技術有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2268)



**BioDlink International
Company Limited**

東曜藥業股份有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1875)

**CONNECTED TRANSACTION
ENTERING INTO OF PROCESS DEVELOPMENT AND
MANUFACTURING SERVICES AGREEMENT**

PROCESS DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT

The WuXi XDC Board and the BioDlink Board are pleased to announce that, on the date of this announcement, BioDlink entered into the Process Development and Manufacturing Services Agreement with WuXi Biologics, pursuant to which BioDlink will provide process development and manufacturing services to WuXi Biologics. The principal terms of the Process Development and Manufacturing Services Agreement are set out below:

Date: 16 June 2026

Parties: (i) BioDlink
(ii) WuXi Biologics

Subject Matter: Pursuant to the Process Development and Manufacturing Services Agreement, BioDlink has agreed to provide WuXi Biologics with process development and manufacturing services in connection with the production of monoclonal antibody intermediates. The services cover processes including cell resuscitation, cell passage, N-stage cell culture, protein purification, excipient addition and other preparation processes for monoclonal antibody intermediates and other biological samples (the “**Process Development and Manufacturing Service**”). BioDlink shall deliver to WuXi Biologics an aggregate of ten (10) batches of monoclonal antibody intermediates that comply with the specifications for the pilot production of the relevant antibodies. For each batch of monoclonal antibody intermediates, a suitable pilot bioreactor (50 L, 200 L or 500 L) will be adopted in accordance with the required output and the full scope of service delivery covers process development or tech transfer, upstream cell expansion, downstream purification and bulk drug substance filling etc.

Each batch shall be delivered within 60 to 90 calendar days after the confirmation of the relevant delivery order, and all orders shall be placed by 31 December 2026.

Consideration: Subject to the above service specifications, the price for each batch of monoclonal antibody intermediates is RMB1,900,000. BioDlink will provide the Process Development and Manufacturing Service to WuXi Biologics at an aggregate fee of RMB19.0 million.

The service fee was determined based on BioDlink's standard pricing schedule with respect to monoclonal antibody intermediates applicable to all its customers, based on the quantity and quality of monoclonal antibody intermediates to be delivered.

When determining the prices set out in the standard pricing schedule, a number of factors that are relevant to the services provided are being taken into account including, but not limited to, (i) the nature, scale, frequency and value of the relevant services; (ii) the complexity of tasks completed by the Company at each stage under each work order; (iii) the resources spent on providing specific services; and (iv) the fees charged for historical transactions of similar nature and the then prevailing market rates. The service fees charged under the Process Development and Manufacturing Services Agreement are consistent with that charged for historical transactions of similar nature and the current prevailing market rates.

Settlement method: WuXi Biologics shall settle the payment in respect of each batch of monoclonal antibody intermediates within 10 working days after the delivery thereof.

Effective period of the Process Development and Manufacturing Services Agreement: From the date of the Process Development and Manufacturing Services Agreement up to 31 December 2026.

REASONS FOR AND BENEFITS OF ENTERING INTO THE PROCESS DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT

The terms of the Process Development and Manufacturing Services Agreement, including the aggregate service fee and other terms set out in the Process Development and Manufacturing Services Agreement, are determined after arm's length negotiations between the parties with reference to the prevailing market prices of similar services and BioDlink's standard pricing schedule with respect to monoclonal antibody intermediates applicable to all its customers.

The Process Development and Manufacturing Services Agreement represents an opportunity for the Group to leverage its monoclonal antibody process development and manufacturing facilities and capabilities to generate meaningful commercial and strategic benefits.

The Group possesses established process development and manufacturing infrastructure, including cell culture laboratories, protein purification platforms and formulation development capabilities that are suitable for providing process development and manufacturing services relating to monoclonal antibody intermediates and other biological samples. By providing the Process Development and Manufacturing Service to WuXi Biologics, the Group will be able to capitalise and utilise existing technical resources, infrastructure equipment that are currently underused. This is expected to have a favourable impact on the Group's financial performance.

Entering into the Process Development and Manufacturing Services Agreement is conducive to BioDlink's goals to deepen its technical knowhow, enhance its processes and strengthen its track record in delivering process development services for monoclonal antibodies and other biological samples. This enhances BioDlink's reputation with existing and potential customers and may support future business development and collaboration opportunities.

In light of the foregoing, the BioDlink Directors (including the independent non-executive BioDlink Directors) are of the view that the Process Development and Manufacturing Services Agreement and the transactions contemplated thereunder are entered into in the ordinary and usual course of business of the Group, on normal commercial terms, and are fair and reasonable and in the interests of BioDlink and the BioDlink Shareholders as a whole.

Having considered the foregoing, the WuXi XDC Directors (including the independent non-executive WuXi XDC Directors) are of the view that the Process Development and Manufacturing Services Agreement and the transactions contemplated thereunder are entered into in the ordinary and usual course of business of the WuXi XDC Group, on normal commercial terms, and are fair and reasonable and in the interests of WuXi XDC and its shareholders as a whole.

INFORMATION ON THE PARTIES

BioDlink

BioDlink is an investment holding company. The BioDlink Group is principally engaged in research and development, manufacturing, and marketing of anti-tumor drugs, CDMO/contract manufacture organization business and license-out of self-developed biological drugs in the PRC.

WuXi Biologics

WuXi Biologics is an exempted company with limited liability incorporated in the Cayman Islands, the shares of which are listed on the Stock Exchange (stock code: 2269). WuXi Biologics is an investment holding company. The WuXi Biologics Group is principally engaged in the provision of end-to-end solutions and services for biologics discovery, development and manufacturing to customers involving in biologics industry.

WuXi XDC

WuXi XDC is an exempted company with limited liability incorporated in the Cayman Islands, the shares of which are listed on the Stock Exchange (stock code: 2268). WuXi XDC is an investment holding company. The WuXi XDC Group is principally engaged in the provision of comprehensive contract research, development and manufacturing organization services, including discovery, process development and Good Manufacturing Practice manufacturing for bioconjugates, monoclonal antibody intermediates and payload linkers associated with bioconjugates.

IMPLICATIONS UNDER THE LISTING RULES

As of the date of this announcement, WuXi Biologics is a controlling shareholder of WuXi XDC, which in turn directly holds approximately 60.67% of the issued share capital of BioDlink. WuXi Biologics is therefore a connected person of both WuXi XDC and BioDlink under the Listing Rules.

For both WuXi XDC and BioDlink, as the highest applicable percentage ratio in respect of the transactions contemplated under the Process Development and Manufacturing Services Agreement is more than 0.1% but less than 5%, the Process Development and Manufacturing Services Agreement is subject to the announcement and reporting requirements but is exempt from the circular and shareholders' approval requirements of both WuXi XDC and BioDlink under Chapter 14A of the Listing Rules.

None of the WuXi XDC Directors and the BioDlink Directors has, or is considered to have, any material interests in the above transactions. Hence, none of them was required to abstain from voting on the relevant board resolution(s) of WuXi XDC and BioDlink approving the entering into of the Process Development and Manufacturing Services Agreement.

DEFINITIONS

In this announcement, the following expressions have the meanings set out below unless the context requires otherwise:

“BioDlink”	BioDlink International Company Limited (東曜藥業股份有限公司), a company incorporated in Hong Kong with limited liability, the Shares of which are listed on the Main Board (stock code: 1875)
“BioDlink Board”	the board of the BioDlink Directors
“BioDlink Directors”	the directors of BioDlink
“BioDlink Group”	BioDlink and its subsidiaries from time to time
“BioDlink Share(s)”	the issued ordinary share(s) of BioDlink

“BioDlink Shareholder(s)”	the registered holder(s) of the BioDlink Share(s)
“connected person(s)”	has the meaning ascribed to it under the Listing Rules
“connected transaction(s)”	has the meaning ascribed to it under the Listing Rules
“controlling shareholder(s)”	has the meaning ascribed to it under the Listing Rules
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange, as amended, supplemented or otherwise modified from time to time
“Main Board”	Main Board of the Stock Exchange
“percentage ratio”	has the meaning ascribed to it under the Listing Rules
“PRC”	the People’s Republic of China, excluding, for the purpose of this announcement, Hong Kong, Macau and Taiwan regions
“Process Development and Manufacturing Services”	has the meaning ascribed to it in the section of this announcement headed “PROCESS DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT”
“Process Development and Manufacturing Services Agreement”	the process development and manufacturing services agreement dated 16 June 2026 and entered into between the BioDlink and WuXi Biologics in respect of the Process Development and Manufacturing Services, which is subject to the announcement and reporting
“RMB”	Renminbi, the lawful currency of the PRC
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“WuXi Biologics”	WuXi Biologics (Cayman) Inc. (藥明生物技術有限公司*), an exempted company incorporated in the Cayman Islands with limited liability, the shares of which are listed on the Main Board (stock code: 2269)
“WuXi Biologics Group”	WuXi Biologics and its subsidiaries from time to time, excluding the Group
“WuXi XDC”	WuXi XDC Cayman Inc. (藥明合聯生物技術有限公司*), an exempted company incorporated in the Cayman Islands with limited liability, the shares of which are listed on the Main Board (stock code: 2268)
“WuXi XDC Board”	the board of directors of WuXi XDC

“WuXi XDC Directors”	the directors of WuXi XDC
“WuXi XDC Group”	WuXi XDC and its subsidiaries from time to time, excluding the Group
“%”	per cent

By order of the WuXi XDC Board

WuXi XDC Cayman Inc.

Dr. Jincal LI

Executive Director and Chief Executive Officer

By order of the BioDlink Board

BioDlink International Company Limited

Dr. Jincal LI

Chairperson

Hong Kong, 17 June 2026

As at the date of this announcement, the WuXi XDC Board comprises (i) Dr. Jincal LI, Mr. Jerry Jingwei ZHANG and Mr. Xiaojie XI as executive directors; (ii) Dr. Zhisheng CHEN, Dr. Jijie GU and Ms. Ming SHI as non-executive directors; and (iii) Dr. Ulf GRAWUNDER, Mr. Kenneth Walton HITCHNER III and Mr. Hao ZHOU as independent non-executive directors.

As at the date of this announcement, the BioDlink Board comprises (i) Dr. Jincal Li as the executive director; (ii) Mr. Xiaojie Xi as the non-executive director; and (iii) Mr. Xin Fan, Dr. Ulf Grawunder and Dr. Chaohong Hu as the independent non-executive Directors.

* *For identification purposes only*